Related Experiment Video
Updated: May 7, 2025
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
4.2K
Dose-dependent pancreatitis risk associated with GLP-1 agonists.
Joyce Hanyue Gu1, Mark Samarneh2
1Lake Erie College of Osteopathic Medicine, Medical School, Seton Hill, PA USA.
Journal of Diabetes and Metabolic Disorders
|January 6, 2025
Summary
Glucagon-like peptide 1 (GLP-1) receptor agonists increase pancreatitis risk in a dose-dependent manner. Higher cumulative doses of these diabetes drugs are linked to a greater chance of developing drug-induced pancreatitis.
Area of Science:
- Pharmacology
- Endocrinology
- Gastroenterology
Background:
- Glucagon-like peptide 1 (GLP-1) receptor agonists are effective type 2 diabetes mellitus (T2DM) treatments.
- A significant risk of drug-induced pancreatitis is associated with GLP-1 agonists.
Purpose of the Study:
- To investigate the dose-dependent relationship between GLP-1 agonists and pancreatitis risk.
- To determine if increasing doses of GLP-1 agonists correlate with a higher incidence of pancreatitis.
Main Methods:
- Retrospective case-control study utilizing the FAERS database.
- Comparison of pancreatitis risk between high and low cumulative dose GLP-1 agonist users.
- Random effects model to combine odds ratios across different GLP-1 agonists.
Main Results:
- A statistically significant higher risk of pancreatitis was observed in patients with high cumulative GLP-1 agonist doses.
- The odds ratio for pancreatitis increased proportionally with the cumulative dose administered.
- This indicates a clear dose-dependent association between GLP-1 agonists and pancreatitis.
Conclusions:
- GLP-1 agonists are associated with a significant risk of pancreatitis.
- This risk escalates with higher cumulative doses of GLP-1 agonists.
- Clinical use of GLP-1 agonists requires careful consideration of pancreatitis risk, especially at higher doses.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
249
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
249
01:23Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117
01:16Insulin: Dosing Regimen and Adverse Effects
121
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
121
01:06Oral Hypoglycemic Agents: Glinides
108
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
108
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
132
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
132
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
104
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
104